Literature DB >> 7895423

Treatment of lupus nephritis: immunosuppression, general therapy, dialysis and transplantation.

W F Clark1.   

Abstract

The treatment of patients with clinical lupus nephritis is based on a combination of our understanding of the natural history of the disease, a large number of anecdotal reports, and a small number of studies which demonstrate statistical treatment benefits. This review is directed towards the treatments (immunosuppressive, general therapy, and end-stage renal failure management) which have been demonstrated to have been, or not to have been, beneficial. Although the prognosis of patients with lupus nephritis is undergoing continuous improvement, this may relate as much to changes in general treatment measures as to specific immunosuppressive schedules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7895423

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  3 in total

1.  SLEN2 (2q34-35) and SLEN1 (10q22.3) replication in systemic lupus erythematosus stratified by nephritis.

Authors:  Ana I Quintero-del-Rio; Jennifer A Kelly; C Phillip Garriott; David C Hutchings; Summer G Frank; Christopher E Aston; John B Harley
Journal:  Am J Hum Genet       Date:  2004-08       Impact factor: 11.025

Review 2.  Fish oil for kidney transplant recipients.

Authors:  Andy K H Lim; Karen J Manley; Matthew A Roberts; Margaret B Fraenkel
Journal:  Cochrane Database Syst Rev       Date:  2016-08-18

Review 3.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.